Dr. Amar Sethi joined VivoSim in November of 2025. He is a physician–scientist and biotechnology executive with 30 years of experience in clinical development, translational medicine, and biomarker innovation. His career is defined by advancing complex therapies through rigorous clinical strategy, science-driven execution, and creation of long-term value for patients and investors. Before joining Vivosim, Dr. Sethi served as Vice President of Clinical Science at Omeros, where he directed protocol design, regulatory engagement, and clinical data strategy across multiple programs in complement-mediated diseases. He also built internal biomarker capabilities to strengthen mechanistic understanding and expand pipeline opportunities. Previously, as President & Chief Medical Officer of Pacific Biomarkers, he guided company strategy, scientific operations, and P&L oversight, driving substantial revenue growth and contributing to the company’s successful acquisition. Earlier roles strengthened his foundation in translational medicine, immunology, clinical assay development, and laboratory operations, providing the scientific and operational depth that underpins his later success in clinical leadership. Dr. Sethi holds an M.D. and Ph.D. and has authored numerous publications and textbook chapters in clinical chemistry and biomarker science.

Tony Lialin joined VivoSim as Chief Commercial Officer in August 2025. A 25+ year commercial leader in genomics, diagnostics, bioinformatics, and imaging, Tony has built global sales teams, closed transformative pharma partnerships, and delivered $10M+ in startup revenue leading to four acquisitions. At Illumina, he closed the company’s largest-ever $157M PO and managed a $403M portfolio across GRAIL, Natera, and AncestryDNA. Previously, he held senior roles at Invivoscribe as Chief Commercial Officer, Oxford Nanoimaging as VP Sales & Customer Success, Loop Genomics as Chief Commercial Officer, Illumina as Executive Strategic Account Manager, and Agilent Technologies. He will lead Sales, Marketing, Partnerships,and Customer Success at VivoSim. He holds a B.A. in Molecular, Cellular & Developmental Biology from the University of California, Santa Cruz.

Mr. Staskey is currently under agreement with Danforth Advisors, LLC and is a seasoned executive with significant experience in managing and leading teams as well as overseeing the financial and operational responsibilities of private and publicly traded life sciences companies. He has served as a Senior Director of Danforth since May 2021. Mr. Staskey has served as the Chief Financial Officer of Azitra, Inc. since October 2022.  From September 2014 to May 2021, Mr. Staskey was employed by EY (formally Ernst & Young), most recently as a managing director in EY’s Financial Accounting and Advisory services practice. Mr. Staskey  received his B.S. of Business Administration from Cleveland State University and is a Certified Public Accountant in the State of Ohio. 

Curtis Tyree is Senior Vice President, Strategy and Business Development, at VivoSim. He is responsible for corporate partnerships, acquisitions, and product strategy. He joined Organovo in 2022 and was responsible for the FXR program acquired by Lilly. Prior to VivoSim, Dr. Tyree held senior positions at HUYABIO, where he helped develop the immunomodulator HIYASTA^™ through approval in Japan. At TorreyPines Therapeutics he presented on the first gamma secretase modulators for Alzheimer’s Disease, and at Ligand Pharmaceuticals helped discover the thrombopoietin mimic Promacta^®. He holds a BSc in Microbiology & Immunology from McGill University and a PhD in Biology from UC San Diego. Dr. Tyree served as a founding member of the Advisory Board and as Adjunct Clinical Assistant Professor of Pharmacy Practice at the KGI School of Pharmacy and Health Sciences. He has served as an instructor and faculty member at the UC San Diego Division of Extended Studies.